Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging
2019-001836-69Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vortioxetine in Mild Cognitive Impairment (MCI) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Whole brain functional connectivity. Started Jul 2021; status: completed.
02
Drugs
vortioxetine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2019-001836-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001836-69.